June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
PROSPECTIVE RANDOMIZED CONTROLLED TRIAL OF COMBINATION RANIBIZUMAB AND KETOROLAC FOR WET AGE-RELATED MACULAR DEGENERATION
Author Affiliations & Notes
  • Andrea Russo
    Univ degli Studi di Brescia - Italy, Brescia, Italy
  • Ciro Costagliola
    Università del Molise, Campobasso, Italy
  • Luisa Delcassi
    Univ degli Studi di Brescia - Italy, Brescia, Italy
  • Mario Romano
    Istituto Clinico Humanitas, Milano, Italy
  • Francesco Semeraro
    Univ degli Studi di Brescia - Italy, Brescia, Italy
  • Footnotes
    Commercial Relationships Andrea Russo, None; Ciro Costagliola, None; Luisa Delcassi, None; Mario Romano, Bausch and Lomb (C); Francesco Semeraro, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4175. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Andrea Russo, Ciro Costagliola, Luisa Delcassi, Mario Romano, Francesco Semeraro; PROSPECTIVE RANDOMIZED CONTROLLED TRIAL OF COMBINATION RANIBIZUMAB AND KETOROLAC FOR WET AGE-RELATED MACULAR DEGENERATION. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4175.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

to evaluate whether ketorolac eyedrops and ranibizumab intravitreal injections would provide additional efficacy over ranibizumab alone in wet age-related macular degeneration.

 
Methods
 

this was a single-site, prospective, open-label, interventional, pilot study of patients with new wet age-related macular degeneration. Sixty eyes were enrolled consecutively and were randomized in a ratio of 1:1 to combination therapy with intravitreal ranibizumab and topical ketorolac, and ranibizumab alone. Ranibizumab was injected monthly for 3 months, then as needed in accordance with standard of care. Patients treated with ketorolac self-administered 1 drop twice a day for 6 months. Patients were followed monthly for 6 months.

 
Results
 

no statistically significant differences were identified in best-corrected visual acuity or the number of injections required. However, the mean 6-month change in central macular thickness in the combination group was 146.53 µm while in the ranibizumab group alone the change was 106.88 µm (P = 0.03). The proportion of eyes experiencing a decrease in CMT of 50 µm or more was also significantly higher in those receiving combination therapy (P = 0.04). There were no safety concerns with the combination therapy.

 
Conclusions
 

this pilot study is the first to prospectively identify an additional effect of ketorolac eyedrops and ranibizumab intravitreal injections compared to treatment with ranibizumab alone in wet age-related macular degeneration.

     
Keywords: 453 choroid: neovascularization • 412 age-related macular degeneration • 700 retinal neovascularization  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×